Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LIPA | P38571 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19870486 | 0.74 | CYP1A2 (0.71) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL20243643 | 0.72 | CYP1A2 (0.48) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL22486487 | 0.70 | TDP1 (0.78) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL19872020 | 0.66 | ALDH1A1 (0.56) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL24859257 | 0.65 | CYP1A2 (0.66) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL22486726 | 0.63 | CYP1A2 (0.77) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL11755634 | 0.63 | CYP1A2 (0.74) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL11193337 | 0.63 | CYP1A2 (0.74) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL10635041 | 0.63 | CYP1A2 (0.64) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL11127560 | 0.63 | CYP1A2 (0.64) | CYP1A2ADRB2ADRB1CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539221-B2 | Method of treating airway diseases with β-adrenergic inverse agonists | EGB ADVISORS, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20100286224-A1 | METHOD OF TREATING AIRWAY DISEASES WITH BETA-ADRENERGIC INVERSE AGONISTS | MCP MANAGER PTY LTD, AS TRUSTEE FOR AND FOR THE BENEFIT OF THE MCP UNIT TRUST 2014 (AU) | 2010-11-11 | — | — | US | disclosed |
| US-20090214643-A1 | IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES | FRANKLIN AMIE E | 2009-08-27 | — | — | US | disclosed |
| US-7528175-B2 | Method of treating airway diseases with beta-adrenergic inverse agonists | INVERSEON, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080254022-A1 | Method of Treating Airway Diseases With Beta-Adrenergic Inverse Agonists | INVERSEON, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070276024-A1 | Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists | INVERSEON , INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276024-A1 | Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists | MRGPRX2, MRGPRX1, GPR52 | CYP1A2 1912/4885ADRB2 29/4885ADRB1 18/4885 |
| US-20100286224-A1 | METHOD OF TREATING AIRWAY DISEASES WITH BETA-ADRENERGIC INVERSE AGONISTS | ADRB2, ADRB1, ADRA2B | CYP1A2 819/4885ADRB2 1/4885ADRB1 2/4885 |
| US-20080254022-A1 | Method of Treating Airway Diseases With Beta-Adrenergic Inverse Agonists | ADRB1, ADRB2, ADRB3 | CYP1A2 922/4885ADRB2 2/4885ADRB1 1/4885 |
| US-20090214643-A1 | IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES | ADRB2, ADRB1, ADRA2A | CYP1A2 969/4885ADRB2 1/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.